Find a clinical trial


If you have questions about clinical trials or want help finding the right one for you, contact our:

Patient Engagement Center Phone: 844-552-2734

This is a preliminary search of all open and enrolling clinical trials across our regions and affiliate organizations that have sponsors' permission to publish to this website.

Please use the filtering options in the right column to refine your search. Otherwise ALL open and enrolling clinical trials will display below.

Viewing Page 3 of 8 | Showing Results 11 - 15 of 40

Long-term, prospective, multinational, parallel-cohort study monitoring safety in patients with MS newly started on fingolimod once daily or treated with another approved disease-modifying therapy

The purpose of this world-wide prospective parallel-cohort study in patients with relapsing forms of MS, either newly treated with fingolimod or...

James Bowen, M.D.
  • Swedish Medical Center

Measurement of Relaxin in the Serum and Cerebrospinal Fluid of Subjects With and Without the Relapsing Form of Multiple Sclerosis

This study will evaluate relaxin (RLX) levels in patients with multiple sclerosis. Key Eligibilities: -Females 18 to 45 years of age.-Patients with...

Stanley Cohan, M.D., Ph.D.
  • Providence St. Vincent Medical Center

TRaditional versus Early Aggressive Therapy for Multiple Sclerosis (TREAT-MS) Trial

FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the...

Elisabeth Lucassen, M.D.
  • Providence St. Vincent Medical Center

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

The purpose of this study is to evaluate the safety and efficacy of elezanumab in subjects with relapsing Multiple Sclerosis (RMS).Key Inclusion...

Kyle E Smoot, M.D.
  • Providence St. Vincent Medical Center

A Pragmatic Trial to Evaluate the Intermediate-term Effects of Early, Aggressive Versus Escalation Therapy in People With Multiple Sclerosis

Inclusion Criteria:-Aged 18-60 years-Meets 2017 McDonald criteria for relapsing-remitting MS [patients with clinically isolated syndrome (CIS) are...

Peiqing Qian, M.D.
  • Swedish Medical Center
Viewing Page 3 of 8 | Showing Results 11 - 15 of 40